• Heart Failure
  • Cardiovascular Clinical Consult
  • Adult Immunization
  • Hepatic Disease
  • Rare Disorders
  • Pediatric Immunization
  • Implementing The Topcon Ocular Telehealth Platform
  • Weight Management
  • Monkeypox
  • Guidelines
  • Men's Health
  • Psychiatry
  • Allergy
  • Nutrition
  • Women's Health
  • Cardiology
  • Substance Use
  • Pediatrics
  • Kidney Disease
  • Genetics
  • Complimentary & Alternative Medicine
  • Dermatology
  • Endocrinology
  • Oral Medicine
  • Otorhinolaryngologic Diseases
  • Pain
  • Gastrointestinal Disorders
  • Geriatrics
  • Infection
  • Musculoskeletal Disorders
  • Obesity
  • Rheumatology
  • Technology
  • Cancer
  • Nephrology
  • Anemia
  • Neurology
  • Pulmonology

Daily Dose: Nerivio Neuromodulation Device for Migraine

Daily Dose: Nerivio Neuromodulation Device for Migraine / Image Credit: ©New Africa/AdobeStock
©New Africa/AdobeStock

Patient Care brings primary care clinicians a lot of medical news every day—it’s easy to miss an important study. The Daily Dose provides a concise summary of one of the website's leading stories you may not have seen.

Last week, we reported on findings from a study published in Advances in Therapy that examined long-term safety, utilization, and efficacy of Theranica’s Nerivio remote electrical neuromodulation (REN) device during 12 consecutive usage months.

The study

The analysis included 409 patients with migraine who were treated with REN for 12 consecutive months, for a total of 39 531 treatments. The average age of the cohort was 45.8 years and the majority (84.6%) were women.

Each patient underwent an average of 8.05 REN treatments over the 12-month period.


At 1 year, consistent efficacy in at least 50% of all treatments per patient was achieved by 74.1% (180 of 243) of patients for pain relief, by 26.0% (67 of 258) for pain freedom, by 70.2% (177 of 252) for functional disability relief, and by 33.7% (85 of 252) for functional disability freedom.

For associated symptoms, treatment response in half or more of patients’ treatments per month was achieved by 43.2% (95 of 220) of patients for photophobia, by 52.7% (107 of 203) of patients for phonophobia, by 70.8% (121 of 171) of patients for nausea/vomiting, and by 73.5% (180 of 245) of patients for at least 1 associated symptom.

Authors' comment

"REN is a safe and well-tolerated acute migraine treatment, with stable efficacy and utilization over 1 year, making it an advantageous non-drug option for the long-term management of this chronic disease."

Click here for more details.

Related Videos
Primary Care is the Answer to the Migraine Care Gap, Says Headache Specialist
© 2024 MJH Life Sciences

All rights reserved.